GLP-1 drugs: who wins the market race?
Wegovy and Zepbound currently dominate the weight loss drug market. But Pfizer, Amgen and others are positioning themselves to grab a share.
GLP-1 agonists (drugs that mimic the appetite-regulating effects of a gut hormone) have grown into one of the most commercially successful drug classes ever. They reduce hunger, lower blood sugar, and are effective for weight loss in many users. Both market leaders, semaglutide (Wegovy, by Novo Nordisk) and tirzepatide (Zepbound, by Eli Lilly), have also been studied for broader health effects including cardiovascular disease.
Competitors entering the field
Pfizer and Amgen are developing their own GLP-1 variants. Both are attempting to differentiate on convenience (pills instead of injections) or through additional mechanisms. The STAT News analysis shows that for newcomers, it is difficult to match what is already proven: safety, efficacy, and broad physician acceptance.
Novo Nordisk and Lilly are responding with new formulations and combination drugs. These include weekly dosing, oral delivery, and combinations with other hormonal mechanisms aimed at preventing muscle loss. That last point matters for long-term use: GLP-1 treatment can sometimes be associated with loss of muscle mass, which poses an added risk for older users.
Relevance for aging
From a longevity perspective, GLP-1 drugs are interesting because earlier research found indications that they may influence biological aging markers. The mechanism behind that effect is not yet well understood. Whether it is clinically relevant with long-term use or at older ages is being investigated in several ongoing studies. The pharmaceutical competition will likely drive faster product improvement and lower costs over the coming years, improving access.